Bioequivalence Study of Atazanavir 300 mg Capsule

Completed · Phase 1

Conditions studied: HIV Infections

In brief

The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.

Key facts

Study ID

NCT00393328

Run by

Bristol-Myers Squibb

People needed

46

Starts

2006-11-01

Expected to finish

2006-12-01

Last updated by the study team

2011-04-08

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female subjects between the ages of 18 to 50 years old with a body mass index (BMI) of 18 to 30 kg/m²
• Prior to enrollment, subjects must have physical and laboratory test findings within normal limits, and women of childbearing potential (WOCBP) must have a negative pregnancy test.

Where it is running

• Local Institution — Hamilton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.